Bagó Juli Rodriguez, Sheets Kevin T, Hingtgen Shawn D
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Biomedical Research Imaging Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Methods. 2016 Apr 15;99:37-43. doi: 10.1016/j.ymeth.2015.08.013. Epub 2015 Aug 24.
Cancers of the brain remain one of the greatest medical challenges. Traditional surgery and chemo-radiation therapy are unable to eradicate diffuse cancer cells and tumor recurrence is nearly inevitable. In contrast to traditional regenerative medicine applications, engineered neural stem cells (NSCs) are emerging as a promising new therapeutic strategy for cancer therapy. The tumor-homing properties allow NSCs to access both primary and invasive tumor foci, creating a novel delivery platform. NSCs engineered with a wide array of cytotoxic agents have been found to significantly reduce tumor volumes and markedly extend survival in preclinical models. With the recent launch of new clinical trials, the potential to successfully manage cancer in human patients with cytotoxic NSC therapy is moving closer to becoming a reality.
脑癌仍然是最大的医学挑战之一。传统的手术和放化疗无法根除弥漫性癌细胞，肿瘤复发几乎不可避免。与传统的再生医学应用不同，工程化神经干细胞（NSCs）正在成为一种有前景的癌症治疗新策略。肿瘤归巢特性使神经干细胞能够到达原发性和侵袭性肿瘤病灶，从而创建了一个新的递送平台。在临床前模型中，用多种细胞毒性药物改造的神经干细胞已被发现能显著减小肿瘤体积并显著延长生存期。随着近期新临床试验的开展，用细胞毒性神经干细胞疗法成功治疗人类癌症患者的可能性正日益接近成为现实。
